WHO Perspectives on medicines Traditional medicine 2 Growing needs and Potential n0.2ma2002 orld Health Organization pulations throughout Africa, Asia and Latin erica use traditional medicine (TM) to help Figure 1 Many developing country populations use TM to help their primary health care needs. As well as be- meet health care needs, while many populations in developed ing accessible and affordable, TM is also often part countries have used CAM at least once of a wider belief system, and considered integral to everyday life and well-being. Meanwhile, in Australia Europe and North America, "complementary and alternative medicine"(CAM)' is increasingly used in Populat parallel to allopathic medicine, particularly for treat traditional medicine India ing and managing chronic disease. Concern about for primary health Rwanda the adverse effects of chemical medicines a desire Tanzania for more personalized health care and greater public access to health information fuel this increased use Populations in Canada (Figure 1: Box 1) But widespread and growing use of TM has createdwmoldve sentries developed countriesAustralia public health challenges in terms of: policy: safety, complementary and efficacy and quality: access; and rational use alternative medicine (Box 2). Policy-makers, health care providers, TM Belgium providers and nongovernmental organizations NGOs) can respond to these challenges, however, Sources: Eisenberg DM ef al 1998: Fisher P& Ward A 1994: Health Canada, 200i and help develop the potential of TM as a source o World Health Organization, 1998; and government reports submitted to WHO health care( Box 3) Box 1 What is traditional medicine? Traditional medicine includes diverse health practices, approaches, knowledge and beliefs incorporating plant, animal and/or mineral ased medicines, spiritual therapies, manual techniques and exercises, applied singularly or in combination to maintain well-being as well as to treat, diagnose or prevent illness. Commonly used therapies and therapeutic techniques Chinese Ayurveda Unani Naturopathy Osteopathy Homeopathy Chiropractic Herbal medicines Acupuncture/acupressur Manual therapies Spiritual therapies rates this therapy/therapeutic technique a sometimes incorporates this therapy/therapeutic technique D s incorporates therapeutic touch traditional medicine"(TM)is used throughout most of this paper. But in some developed countries, the term'comp medicine"(CAM) is used where the dominant health care system is based on allopathic medicine, or where TM has not been incorporated into the 2 Traditional medicine practitioners are generally understood to be nal healers, bone setters, herbalists, etc. Traditional medicine providers include both traditional medicine practitioners and allopathic medicine professionals such as doctors, dentists and nurses who provide TM/CAM therapies to their atients-e.g. many allopathic doctors also use acupuncture to treat their patients. Page 1: WHO Policy Perspectives on edicines- Traditional medicine -Growing needs and Potential
Page 1: WHO Policy Perspectives on Medicines — Traditional Medicine – Growing Needs and Potential WHO Policy Perspectives on Medicines No. 2 May 2002 World Health Organization Geneva Traditional Medicine – Growing Needs and Potential Populations throughout Africa, Asia and Latin America use traditional medicine (TM) to help meet their primary health care needs. As well as being accessible and affordable, TM is also often part of a wider belief system, and considered integral to everyday life and well-being. Meanwhile, in Australia, Europe and North America, “complementary and alternative medicine” (CAM)1 is increasingly used in parallel to allopathic medicine, particularly for treating and managing chronic disease. Concern about the adverse effects of chemical medicines, a desire for more personalized health care and greater public access to health information, fuel this increased use (Figure 1; Box 1). But widespread and growing use of TM has created public health challenges in terms of: policy; safety, efficacy and quality; access; and rational use (Box 2). Policy-makers, health care providers, TM providers2 and nongovernmental organizations (NGOs) can respond to these challenges, however, and help develop the potential of TM as a source of health care (Box 3). Benin India Rwanda Tanzania Uganda Canada Australia France USA Belgium Ethiopia 90% 70% 70% 70% 60% 60% 70% 48% 49% 42% 31% Populations in developed countries who have used complementary and alternative medicine at least once Populations using traditional medicine for primary health care Sources: Eisenberg DM et al, 1998; Fisher P & Ward A, 1994; Health Canada, 2001; World Health Organization, 1998; and government reports submitted to WHO. Figure 1 Many developing country populations use TM to help meet health care needs, while many populations in developed countries have used CAM at least once Box 1 What is traditional medicine? Traditional medicine includes diverse health practices, approaches, knowledge and beliefs incorporating plant, animal and/or mineral based medicines, spiritual therapies, manual techniques and exercises, applied singularly or in combination to maintain well-being, as well as to treat, diagnose or prevent illness. Commonly used therapies and therapeutic techniques Chinese Ayurveda Unani Naturopathy Osteopathy Homeopathy Chiropractic Medicine Herbal medicines Acupuncture/acupressure Manual therapies Spiritual therapies Exercises = commonly incorporates this therapy/therapeutic technique = sometimes incorporates this therapy/therapeutic technique = incorporates therapeutic touch 1 The term “traditional medicine” (TM) is used throughout most of this paper. But in some developed countries, the term “complementary and alternative medicine” (CAM) is used where the dominant health care system is based on allopathic medicine, or where TM has not been incorporated into the national health care system. 2 Traditional medicine practitioners are generally understood to be traditional healers, bone setters, herbalists, etc. Traditional medicine providers include both traditional medicine practitioners and allopathic medicine professionals such as doctors, dentists and nurses who provide TM/CAM therapies to their patients – e.g. many allopathic doctors also use acupuncture to treat their patients
Safety, efficacy and quality: Box 2 rey messages for policy-makers crucial to extending TI care g TM includes diverse health practices, approaches, knowledge and beliefs, incorporating medicines from Allopathic practitioners emphasize the scientific ap- plant, animal and/or mineral sources, spiritual proach of allopathic medicine, and contend that it therapies, manual techniques and exercises is free of cultural values. TM therapies have developed rather differently, having been very much influenced e TM is widely and increasingly used for a wide by the culture and historical conditions within which spectrum of diseases by people in both developed they first evolved. Their common basis is an holistic and developing countries. approach to life, equilibrium between the mind. g a growing number of countries are adopting national olicies on TM and developing specific regulatory capacity, especially for herbal medicines. Increasingly ountries are defining the role that TM plays in Box 3 policies and actions checklist national health care delivery systems * Scientific evidence from randomized clinical trials is Safety, efficacy and quality strong for many uses of acupuncture, for some herbal Establish registration and licensing of providers medicines and for some of the manual therapies Establish national regulation and registration of g. Nevertheless. much of the scientific literature on tm herbal medicines provides inadequate evidence on safety and efficacy Establish safety monitoring of herbal medicines and dividual case reports and patient series, with no ther TM therapies. control or comparison group e Provide selective support for clinical research into g Over-harvesting of medicinal plants threatens some use of TM for treating country's common health problems Protection and preservation of TM knowledge is g Develop national standards, and technical guidelines essential to ensure access to traditional forms of and methodology, for evaluating safety, efficacy and health care and respect for those who hold TM quality of TM knowledge. Intellectual property rights issues require g. Develop national pharmacopoeia and monographs of national and international attention medicinal plants. g Identify safe and effective TM therapies and Policy: generating sound action in tin e Support research into safe and effective treatme for those diseases which represent the greatest As of the year 2000, 25 countries reported having burden, particularly for poorer populations. f Recognize role of TM providers in providing health a national TM policy. Such a policy provides a sound basis for defining the role of TM in national health care delivery, ensuring that the necessary regulatory and g Optimize and upgrade the skills of TM providers. legal mechanisms are created for promoting and g Protect TM knowledge through recording and maintaining good practice, that access is equitable preservation. and that the authenticity, safety e Cultivate and conserve medicinal plants to ensure and efficacy of therapies are their sustainable use Rational use A national TM policy is urgently g Develop training guidelines for country's most needed in those developing commonly used TM therapies countries where the population e Strengthen and increase organization of TM depends largely on TM for health care, but without its having been well evaluated or integrated into the national health e Strengthen cooperation between TM providers and other health care providers. system. Many developed countries are now also find- ing that TM issues concerning, for example, safety f. Make reliable information on proper use of TM and quality, licensing of providers and standards therapies and products available for consumers of training, and priorities for research, can best g Improve communication between health care be tackled within the framework of a national tm providers and their patients concerning use of TM Page 2: WHO Policy Pers on medicines- Traditional medicine- Growing needs and Potential
Page 2: WHO Policy Perspectives on Medicines — Traditional Medicine – Growing Needs and Potential Box 2 Key messages for policy-makers ✥ TM includes diverse health practices, approaches, knowledge and beliefs, incorporating medicines from plant, animal and/or mineral sources, spiritual therapies, manual techniques and exercises. ✥ TM is widely and increasingly used for a wide spectrum of diseases by people in both developed and developing countries. ✥ A growing number of countries are adopting national policies on TM and developing specific regulatory capacity, especially for herbal medicines. Increasingly, countries are defining the role that TM plays in national health care delivery systems. ✥ Scientific evidence from randomized clinical trials is strong for many uses of acupuncture, for some herbal medicines and for some of the manual therapies. ✥ Nevertheless, much of the scientific literature on TM provides inadequate evidence on safety and efficacy: individual case reports and patient series, with no control or comparison group. ✥ Over-harvesting of medicinal plants threatens some ecosystems. ✥ Protection and preservation of TM knowledge is essential to ensure access to traditional forms of health care and respect for those who hold TM knowledge. Intellectual property rights issues require national and international attention. Policy: generating sound action in TM As of the year 2000, 25 countries reported having a national TM policy. Such a policy provides a sound basis for defining the role of TM in national health care delivery, ensuring that the necessary regulatory and legal mechanisms are created for promoting and maintaining good practice, that access is equitable, and that the authenticity, safety and efficacy of therapies are assured. A national TM policy is urgently needed in those developing countries where the population depends largely on TM for health care, but without its having been well evaluated or integrated into the national health system. Many developed countries are now also finding that TM issues concerning, for example, safety and quality, licensing of providers and standards of training, and priorities for research, can best be tackled within the framework of a national TM policy. Safety, efficacy and quality: crucial to extending TM care Allopathic practitioners emphasize the scientific approach of allopathic medicine, and contend that it is free of cultural values. TM therapies have developed rather differently, having been very much influenced by the culture and historical conditions within which they first evolved. Their common basis is an holistic approach to life, equilibrium between the mind, Box 3 Policies and actions checklist Safety, efficacy and quality ✥ Establish registration and licensing of providers. ✥ Establish national regulation and registration of herbal medicines. ✥ Establish safety monitoring of herbal medicines and other TM therapies. ✥ Provide selective support for clinical research into use of TM for treating country’s common health problems. ✥ Develop national standards, and technical guidelines and methodology, for evaluating safety, efficacy and quality of TM. ✥ Develop national pharmacopoeia and monographs of medicinal plants. Access ✥ Identify safe and effective TM therapies and products. ✥ Support research into safe and effective treatment for those diseases which represent the greatest burden, particularly for poorer populations. ✥ Recognize role of TM providers in providing health care. ✥ Optimize and upgrade the skills of TM providers. ✥ Protect TM knowledge through recording and preservation. ✥ Cultivate and conserve medicinal plants to ensure their sustainable use. Rational use ✥ Develop training guidelines for country’s most commonly used TM therapies. ✥ Strengthen and increase organization of TM providers. ✥ Strengthen cooperation between TM providers and other health care providers. ✥ Make reliable information on proper use of TM therapies and products available for consumers. ✥ Improve communication between health care providers and their patients concerning use of TM
body and their environment, and an emphasis on Optimal use and expanded credibility of TM will there- health rather than on disease. Generally, the provider fore depend on developing an evidence base for focuses on the overall condition of the individual pa- safety and efficacy. This means consolidating existing tient, rather than on the particular ailment or disease national and international studies, and supporting from which the patient is suffering new research to fill evidence gaps This more complex approach to health care makes Access: making Tm evaluation highly difficult since so many factors must available and affordable be taken into account ds poorest countries are most in ven evaluating TM products, such as herbal medi- cines, can prove very difficult. This is because herbal need of inexpensive, effective treatments for diseases WHO estimates that one-third of medicine quality is influenced by several factors, such as when and where the raw materials were collected the global population still lacks regular and accuracy of plant identification access to essential drugs, and that in he poorest parts of Africa and Asia, this figure rises to over 50% In these re- Nevertheless, many TM practices and products have gions, some form of TM is often a more widely avail- been used for a considerable period of time And able and more affordable source of health care some scientific evidence points to promising poten- However, if access to TM is to be increased to help tiaL. Acupuncture's efficacy in relieving pain an improve health status, two issues must be tackle nausea, for instance, has been conclu- They are: development of reliable standard indi sively demonstrated and is now cators to accurately measure levels of access, and acknowledged worldwide. For collection of qualitative data to identify constraints Ks herbal medicines (Figure 2). some to extending access. of the best-known evidence for effi cacy of a herbal product, besides Safe and effective TM therapies must also be identi- that for Artemisia annua for manag- fied, to provide a sound basis for efforts to promote ing malaria, concerns St Johns Wort, for TM. The focus should be on safe and effective trea treating mild to moderate depression ments for diseases which represent the greatest bur- den for poor populations, i.e. for malaria and HIV/AIDS At the same time, a growing number of reports docu- ment the sometimes fatal adverse effects of misuse Cooperation between TM providers and community of traditional therapies and use of therapies for which health workers needs to be increased too. In some information on safety is lacking countries- notably in Africa - links between, for ex ample, traditional birth attendants and primary health are providers are being strengthened. But in many others, these two types of heath care provider work Figure 2 Good evidence of efficacy exists for some in isolation from one another. TM therapies then risk herbal medicines-but evaluation is inadequate being sidelined. Opportunities to deliver health mes- sages are also lost. At the same time, some TM provid- 34% ers lack knowledge of primary health care and per- same as compared placebo benefit as compared form practices that carry health risks. The challenge to placebo is to recognize and ensure that the health skills and knowledge of TM providers are optimized other access issues relate to protection of TM knowl- edge and sustainable use of natural resources. Many methods and regimes can be used for protecting TM knowledge, such as report benefit unlike creating a national inventory of medicinal plants, recording TM of randomized clinical trials(RCTs)showing benefit of herbal medicines knowledge, and creating a (based on 50 RCTs with 10 herbal medicines for 18 therapeutic indications) national policy on protection of TM knowledge. Sustainable use Souce: Based on data in Herbalmedicines an evidence based look thero can also be promoted by several beutics Letter, ssue 25, June-July 1998 means, including adoption of good agricultural practices Page 3: WHO Policy Perspectives on edicines- Traditional medicine -Growing needs and Potential
Page 3: WHO Policy Perspectives on Medicines — Traditional Medicine – Growing Needs and Potential body and their environment, and an emphasis on health rather than on disease. Generally, the provider focuses on the overall condition of the individual patient, rather than on the particular ailment or disease from which the patient is suffering. This more complex approach to health care makes TM very attractive to many. But it also makes scientific evaluation highly difficult since so many factors must be taken into account. Even evaluating TM products, such as herbal medicines, can prove very difficult. This is because herbal medicine quality is influenced by several factors, such as when and where the raw materials were collected, and accuracy of plant identification. Nevertheless, many TM practices and products have been used for a considerable period of time. And some scientific evidence points to promising potential. Acupuncture’s efficacy in relieving pain and nausea, for instance, has been conclusively demonstrated and is now acknowledged worldwide. For herbal medicines (Figure 2), some of the best-known evidence for efficacy of a herbal product, besides that for Artemisia annua for managing malaria, concerns St John’s Wort, for treating mild to moderate depression. At the same time, a growing number of reports document the sometimes fatal adverse effects of misuse of traditional therapies and use of therapies for which information on safety is lacking. 18% same as compared to placebo 34% benefit as compared to placebo 48% report benefit unlikely — due to design or analytic flaw % of randomized clinical trials (RCTs) showing benefit of herbal medicines (based on 50 RCTs with 10 herbal medicines for 18 therapeutic indications) Figure 2 Good evidence of efficacy exists for some herbal medicines – but evaluation is inadequate Optimal use and expanded credibility of TM will therefore depend on developing an evidence base for safety and efficacy. This means consolidating existing national and international studies, and supporting new research to fill evidence gaps. Access: making TM available and affordable The world’s poorest countries are most in need of inexpensive, effective treatments for diseases. WHO estimates that one-third of the global population still lacks regular access to essential drugs, and that in the poorest parts of Africa and Asia, this figure rises to over 50%. In these regions, some form of TM is often a more widely available and more affordable source of health care. However, if access to TM is to be increased to help improve health status, two issues must be tackled. They are: development of reliable standard indicators to accurately measure levels of access, and collection of qualitative data to identify constraints to extending access. Safe and effective TM therapies must also be identified, to provide a sound basis for efforts to promote TM. The focus should be on safe and effective treatments for diseases which represent the greatest burden for poor populations, i.e. for malaria and HIV/AIDS. Cooperation between TM providers and community health workers needs to be increased too. In some countries – notably in Africa – links between, for example, traditional birth attendants and primary health care providers are being strengthened. But in many others, these two types of heath care provider work in isolation from one another. TM therapies then risk being sidelined. Opportunities to deliver health messages are also lost. At the same time, some TM providers lack knowledge of primary health care and perform practices that carry health risks. The challenge is to recognize and ensure that the health skills and knowledge of TM providers are optimized. Other access issues relate to protection of TM knowledge and sustainable use of natural resources. Many methods and regimes can be used for protecting TM knowledge, such as creating a national inventory of medicinal plants, recording TM knowledge, and creating a national policy on protection of TM knowledge. Sustainable use can also be promoted by several means, including adoption of good agricultural practices. Source: Based on data in Herbal medicines: an evidence based look. Therapeutics Letter, Issue 25, June–July 1998
Rational use: ensuring WHO Expert Committees and Collaborating Centres appropriateness for Traditional Medicine, as well as through work with a broad range of partners with diverse interests in TM The strategy provides a framework for action for WHO Rational use of TM has many aspects, including: quali- fication and licensing of providers: proper use of and its partners, to enable Tm to play a far greater good-quality products; good communication be- role in reducing excess mortality and morbidity, es- tween TM providers, allopathic practitioners and rates four objectives relating to: policy: safety, efficacy patients; and provision of scientific information and and quality: access; and rational use (Table 1) guidance for the public knowledge, qualifications and implement it. Use of critical indicators(such as num- training of TM providers are ad- ber of countries with a national tradi equate. Secondly, using training to ensure that TM providers and tional medicine policy, and number of countries with laws and regula- modern health care profession- tions on herbal medicines) will help is understand and appreciate measure progress under each of the complementarity of the the strategy objectives. Addition- types of health care they offer. ally, several surveys relating to policy and regulation and use, will be carried out Proper use of good quality products can also do much to reduce risks associated with TM products in cooperation with Member States and NGOs to assess progress. such as herbal medicines. However, regulation and registration of herbal medicines are not well devel- oped in most countries, and the quality of ucts sold is generally not guaranteed. Mor many Box 4 Organizations working on are sold as over-the-counter or dietary supplements traditional medicine issues Much more stringent control of TM products Nongovernmental organizations(NGOs) Worldwide, many NGOs are working in the field of More work is also needed to raise aware- traditional medicine. Just a few examples are given ness of safe and appropriate use of TM Side-effects following reactions between orationhttp://www.cochrane.org herbal medicines and chemical drugs can cochrane/general. htm occur. Yet many patients do not inform their FordFoundation:http://www.fordfound.org allopathic practitioners that they are taking herbal Pro.me.TrA:http://www.prometra.org/ medicines Information, education and communica- WorldWideFundforNature:http://www.panda.org tion strategies could overcome such problems WorldConservationUnion:http://www.iucn.org Global professional associations WHO's role in meeting Liga Medicorum Homeopathica Internationalis (iNternationalHomeopathicMedicalLeague):http:// challenges in TIll /ww.Imhinet/ WorldFederationofcHiropractichttp:/www.wfc.org To meet growing challenges in the area of TM, WHO WorldSelf-medicAtionIndustryhttp://www.wsmi.org has formulated a comprehensive working TM strat- egy for 2002-2005. Flexible enough to integrate the Specific initiatives also exist needs of each WHO Region and Member State, it also Global Initiative for Traditional Systems of Health addresses issues relating to national policy, safety http://users.ox.ac.uk/-gree0179/ and efficacy, access, and rational use of TM Research Initiative on traditional Anti-malarial Methods. http://mim.nihgovlenglish/partnerships/ritam eveloped through applica tation with WHO Regional Offices and Member States 3 Given the considerable regional diversity in the use and role of TM, and the difficulties that persist in defining precise terminology for describing TM therapies and products, and in assessing the reliability of methodologies used to collect TM data, the strategy must be regarded as a working documen only, that may later have to be modified Page 4: WHO Policy Perspectives on edicines- Traditional medicine -Growing needs and Potent
Page 4: WHO Policy Perspectives on Medicines — Traditional Medicine – Growing Needs and Potential Rational use: ensuring appropriateness Rational use of TM has many aspects, including: qualification and licensing of providers; proper use of good-quality products; good communication between TM providers, allopathic practitioners and patients; and provision of scientific information and guidance for the public. Challenges in education and training are at least twofold. Firstly, ensuring that the knowledge, qualifications and training of TM providers are adequate. Secondly, using training to ensure that TM providers and modern health care professionals understand and appreciate the complementarity of the types of health care they offer. Proper use of good quality products can also do much to reduce risks associated with TM products such as herbal medicines. However, regulation and registration of herbal medicines are not well developed in most countries, and the quality of herbal products sold is generally not guaranteed. Moreover, many are sold as over-the-counter or dietary supplements. Much more stringent control of TM products is needed. More work is also needed to raise awareness of safe and appropriate use of TM. Side-effects following reactions between herbal medicines and chemical drugs can occur. Yet many patients do not inform their allopathic practitioners that they are taking herbal medicines. Information, education and communication strategies could overcome such problems. WHO’s role in meeting challenges in TM To meet growing challenges in the area of TM, WHO has formulated a comprehensive working TM strategy for 2002–2005.3 Flexible enough to integrate the needs of each WHO Region and Member State, it also addresses issues relating to national policy, safety and efficacy, access, and rational use of TM. The strategy was developed through broad consultation with WHO Regional Offices and Member States, WHO Expert Committees and Collaborating Centres for Traditional Medicine, as well as through work with a broad range of partners with diverse interests in TM. The strategy provides a framework for action for WHO and its partners, to enable TM to play a far greater role in reducing excess mortality and morbidity, especially among impoverished populations. It incorporates four objectives relating to: policy; safety, efficacy and quality; access; and rational use (Table 1). Many of the organizations and individuals who contributed to development of the WHO Traditional Medicine Strategy 2002–2005 will work with WHO to implement it. Use of critical indicators (such as number of countries with a national traditional medicine policy, and number of countries with laws and regulations on herbal medicines) will help measure progress under each of the strategy objectives. Additionally, several surveys relating to policy, and regulation and use, will be carried out in cooperation with Member States and NGOs to assess progress. 3 Given the considerable regional diversity in the use and role of TM, and the difficulties that persist in defining precise terminology for describing TM therapies and products, and in assessing the reliability of methodologies used to collect TM data, the strategy must be regarded as a working document only, that may later have to be modified. Box 4 Organizations working on traditional medicine issues Nongovernmental organizations (NGOs) Worldwide, many NGOs are working in the field of traditional medicine. Just a few examples are given here. Cochrane Collaboration: http://www.cochrane.org/ cochrane/general.htm Ford Foundation: http://www.fordfound.org/ PRO.ME.TRA: http://www.prometra.org/ World Wide Fund for Nature: http://www.panda.org/ World Conservation Union: http://www.iucn.org/ Global professional associations Liga Medicorum Homeopathica Internationalis (International Homeopathic Medical League): http:// www.lmhi.net/ World Federation of Chiropractic: http://www.wfc.org World Self-Medication Industry: http://www.wsmi.org/ Specific initiatives also exist Global Initiative for Traditional Systems of Health: http://users.ox.ac.uk/~gree0179/ Research Initiative on Traditional Anti-malarial Methods: http://mim.nih.gov/english/partnerships/ritam_ application.pdf
Table 1 WHO traditional medicine strategy 2002-2005: objectives, components and expected outcomes Objectives Components Expected outcomes POLICY: Integrate TM/CAM 1. Recognition of TM/CAM 1.1 Increased government support and recogniti care Help countries to develop national of TM/CAM, through comprehensive national systems, as appropriate, policies and programmes on TM/CAM policies on TM/CAM by developing and 1.2 Relevant TM/CAM integrated into national implementing national ealth care system services TM/CAM polici 2. Protection and preservation of 2.1 Increased recording and preservation of indigenous TM knowledge relating includi to health velopment of digital TM libraries protect their indigenous TM knowledge SAFETY, EFFICACY AND 3. Evidence base for tm/caM 3.1 Increased access to and extent of knowledge of QUALITY: Promote the Increase access to and extent of TM/CAM through networking and exchange of safety, efficacy and quality nowledge of the safety, efficacy and accurate information of TM/CAM by expanding quality of TM/CAM, with an emphasis on 3.2 Technical reviews of research on use of Tm/ CAM the knowledge base on riority health problems such as malaria for prevention, treatment and management of TM/CAM, and by providing and HIVIAIDS common diseases and conditions guidance on regulatory 3.3 Selective support for clinical research into use of and quality assurance M/CAM for priority health problems such as malaria and HIVIAIDS, and common diseases 4. Regulation of herbal medicines 4.1 National regulation of herbal medicines, including pport countries to establish effective egistration, established and implemented regulatory systems for registration and 4.2 Safety monitoring of herbal medicines and other quality assurance of herbal medicine TM/CAM therapies 5. Guidelines on safet acy and quality 5.1 Technical guidelines and methodology for evaluating safety, efficacy and quality of TM/CAM technical guidelines for ensuring the safety, 5.2 Criteria for evidence-based data on safety, efficacy efficacy and quality control of herbal and quality of TM/CAM therapies medicines and other TM/CAM products and ACCESS: Increase the 6. Recognition of role of TM/CAM 6.1 Criteria and indicators, where possible, to measur availability and affordability providers in health care cost-effectiveness and equitable access to TM/CAM of TM/CAM, as appropriate, Advocate recognition of TM/CAM 6.2 Increased of TM/CAM through national with an emphasis providers in health care by encouraging alth services access for poor populations interaction and dialogue between TM/CAM 6. 3 Increased number of national organizations of providers and allopathic practitioners TM/CAM provi 7. Protection of to medicinal plants of medicinal plants 7. 2. Sustainable use of medicinal plant resources RATIONAL USE: Promote 8. Proper use of TM/CAM by health providers 8.1 Basic training in commonly used TM/CAM therapeutically sound use ncrease capacity of TM/CAM providers to therapies for allopathic practitioners of appropriate TM/CAM make proper use of TM/CAM products and 8.2 Basic training in primary health care for TM by providers and consumers therapies 9. Proper use of TM/CAM ners 9.1 Reliable information for consumers on proper use Increase capacity of consumers to make of TM/CAM therapies informed decisions about use of TM/CAM 9.2 Improved communication between allopathic products and therapies practioners and their patients concerning use of TM/CAM With the exception of China, the Democratic People's Republic of Korea, the Republic of Korea and viet Nam, such integration ho In some countries national assessment wil therefore be needed to ascertain which IM/CAM modalities can be best integrated into the national health care Page 5: WHO Policy Perspectives on edicines- Traditional medicine -Growing needs and Potent
Page 5: WHO Policy Perspectives on Medicines — Traditional Medicine – Growing Needs and Potential Table 1 WHO traditional medicine strategy 2002–2005: objectives, components and expected outcomes Objectives Components Expected outcomes POLICY: Integrate TM/CAM 1. Recognition of TM/CAM 1.1 Increased government support and recognition with national health care Help countries to develop national of TM/CAM, through comprehensive national systems, as appropriate, policies and programmes on TM/CAM policies on TM/CAM by developing and 1.2 Relevant TM/CAM integrated into national implementing national health care system services TM/CAM policies* and programmes 2. Protection and preservation of 2.1 Increased recording and preservation of indigenous TM knowledge relating indigenous knowledge of TM, including to health development of digital TM libraries Help countries to develop strategies to protect their indigenous TM knowledge SAFETY, EFFICACY AND 3. Evidence base for TM/CAM 3.1 Increased access to and extent of knowledge of QUALITY: Promote the Increase access to and extent of TM/CAM through networking and exchange of safety, efficacy and quality knowledge of the safety, efficacy and accurate information of TM/CAM by expanding quality of TM/CAM, with an emphasis on 3.2 Technical reviews of research on use of TM/CAM the knowledge base on priority health problems such as malaria for prevention, treatment and management of TM/CAM, and by providing and HIV/AIDS common diseases and conditions guidance on regulatory 3.3 Selective support for clinical research into use of and quality assurance TM/CAM for priority health problems such as standards malaria and HIV/AIDS, and common diseases 4. Regulation of herbal medicines 4.1 National regulation of herbal medicines, including Support countries to establish effective registration, established and implemented regulatory systems for registration and 4.2 Safety monitoring of herbal medicines and other quality assurance of herbal medicines TM/CAM therapies 5. Guidelines on safety, efficacy and quality 5.1 Technical guidelines and methodology for Develop and support implementation of evaluating safety, efficacy and quality of TM/CAM technical guidelines for ensuring the safety, 5.2 Criteria for evidence-based data on safety, efficacy efficacy and quality control of herbal and quality of TM/CAM therapies medicines and other TM/CAM products and therapies ACCESS: Increase the 6. Recognition of role of TM/CAM 6.1 Criteria and indicators, where possible, to measure availability and affordability providers in health care cost-effectiveness and equitable access to TM/CAM of TM/CAM, as appropriate, Advocate recognition of TM/CAM 6.2 Increased provision of TM/CAM through national with an emphasis on providers in health care by encouraging health services access for poor populations interaction and dialogue between TM/CAM 6.3 Increased number of national organizations of providers and allopathic practitioners TM/CAM providers 7. Protection of medicinal plants 7.1 Guidelines for good agriculture practice in relation Promote sustainable use and cultivation to medicinal plants of medicinal plants 7.2. Sustainable use of medicinal plant resources RATIONAL USE: Promote 8. Proper use of TM/CAM by health providers 8.1 Basic training in commonly used TM/CAM therapeutically sound use Increase capacity of TM/CAM providers to therapies for allopathic practitioners of appropriate TM/CAM make proper use of TM/CAM products and 8.2 Basic training in primary health care for TM by providers and consumers therapies practitioners 9. Proper use of TM/CAM by consumers 9.1 Reliable information for consumers on proper use Increase capacity of consumers to make of TM/CAM therapies informed decisions about use of TM/CAM 9.2 Improved communication between allopathic products and therapies practioners and their patients concerning use of TM/CAM * With the exception of China, the Democratic People’s Republic of Korea, the Republic of Korea and Viet Nam, such integration has nowhere taken place. In some countries national assessment will therefore be needed to ascertain which TM/CAM modalities can be best integrated into the national health care system
WHO/EDM/2002. 4 Distr. General Rey documents World Health Organization. Promoting the Role of Tradi- tional Medicine in Health Systems: a Strategy for the Astin JA. Why patients use alternative medicine: results of African Region 2001-2010. Harare, WHO Regional a national study. Journal of the American Medical Office for Africa, 2000(document reference AFR/RC50 Bodeker G et al. A regional task force on traditional Zollman C vickers AJ. ABC of Complementary Medicine. medicine and AIDS. Lancet, 2000, 8 April, 355(9211): London, BMJ Books, 2000(reprinted from a series of articles that appeared in the British Medical Journal during 1999) Bodeker G Lessons on integration from the developing worids experience. British Medical Journal, 2001 Seealsohttp://www.who.int/medicines/ 322:164-167(20 January Chaudhury RR Rafei UM, eds. Traditional Medicine in Contacts at WHO Headquarters: Asia. New Delhi, WHO Regional Office for South-East Asia, 2002(SEARO Regional Publications No. 39) Essential Drugs and medicines Policy Eisenberg DM et al. Trends in alternative medicine use in Health Technology and Pharmaceuticals Cluster the United States 1990-1997: re a follow-u WHO Headquarters, Geneva, Switzerland: national survey. Journal of the Dr Jonathan Quick Fisher P& Ward A Medicine in Europe: complementary Tel: +41 22 791 4443 Email: quickj@who int medicine in Europe. British Medical Journal, 1994, 309 aoul nan Traditional medicin Health Canada. Perspectives on Complementary and Tel: +41 22 791 3639 Email: zhang @who int Prepared for Health Canada. Ottawa, Health Canada, Contacts in WHO Regional Ofices Herbal medicines: an evidence based look Therapeutics Regional office for Africa: Letterlssue25,June-july1998.http://www.ti.ubc.ca Dr Ossy Kasilo Jonas WB. Alternative medicine: learning from the past, Tel: +263 4 790 233 E-mail: kasilo@whoafr org examining the present, advancing to the future Regional Office for the Americas: ditorial) Journal of the American Medical Associa- Dr rosario d'alessio tion1998.280(18):1616-1618 egional Adviser for Pharmaceuticals World Health Organization Report: Technical Briefing on Tel:+1 202 974 3282 E-mail: dalessir@paho. org Traditional Medicine Forty-ninth Regional Committee Dr Sandra Land meeting, Manila, Philippines, 18 September 1998. Manila, egional Adviser, Local Health Services WHO Regional Office for the Western Pacific, 1998 Tel: +1 202 974 3214 E-mail: landsand@ paho. org World Health Organization. Consultation Meeting on Regional Office for the Eastern mediterranean Traditional Medicine and Modern Medicine: Harmon Mr Peter graaff izing the Two Approaches. Geneva, World Health egional Adviser, Essential Drugs and biologicals Organization, 1999(document reference (WP)TRM/ICP/ Tel: +20 2 276 5301 E-mail: graaff@emro. who int TRM/001/RB/98-RS/99/GE/ 32(CHN)) Regional Office for Europe World Health Organization. Development of National Mr Kees de jonckheere Policy on Traditional Medicine. A Report of the Work- Regional Adviser, Pharmaceuticals Tel: +45 3 917 1717 E-mail: cjo@who. dk Medicine, 11-15 October 1999, Bejing, China. Manila, Regional Office for South-East Asia: Dr Krisantha Weerasuriya World Health Organization Regional Consultation on egional Adviser Development of Traditional Medicine in South-East Asia Essential Drugs and vaccines Region, 1999. New Delhi, WHO Regional Office for South- Tel: +91 11 331 7804 E-mail: weerasuriyak @whose. org Regional Office for the We World Health Organization. General Guidelines for Meth- Dr Chen Ke odologies on Research and Evaluation of Traditional Traditional Medicines adviser Medicine. Geneva, World Health Organization, 2000 Tel: +63 2 528 9948 E-mail: chenk @who.org.ph (document reference WHO/EDM/TRM/2000. 1) This document is not a formal publication of the world Health Organization (WHO), and all rights are reserved by ization. T nd translated, in part or in whole, but not for sale nor for use in with commercial purposes. The named authors are solely the responsibility of those authors Page 6: WHO Policy Perspectives on edicines- Traditional medicine -Growing needs and Potential
Page 6: WHO Policy Perspectives on Medicines — Traditional Medicine – Growing Needs and Potential Key documents Astin JA. Why patients use alternative medicine: results of a national study. Journal of the American Medical Association, 1998, 279(19):1548–1553. Bodeker G et al. A regional task force on traditional medicine and AIDS. Lancet, 2000, 8 April, 355(9211): 1284. Bodeker G. Lessons on integration from the developing world’s experience. British Medical Journal, 2001, 322:164–167 (20 January). Chaudhury RR & Rafei UM, eds. Traditional Medicine in Asia. New Delhi, WHO Regional Office for South-East Asia, 2002 (SEARO Regional Publications No.39). Eisenberg DM et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. Journal of the American Medical Association, 1998, 280(18):1569–1575. Fisher P & Ward A. Medicine in Europe: complementary medicine in Europe. British Medical Journal, 1994, 309: 107–111. Health Canada. Perspectives on Complementary and Alternative Health Care. A Collection of Papers Prepared for Health Canada. Ottawa, Health Canada, 2001. Herbal medicines: an evidence based look. Therapeutics Letter. Issue 25, June–July 1998. http://www.ti.ubc.ca. pages/letter25.htm. Jonas WB. Alternative medicine: learning from the past, examining the present, advancing to the future [editorial]. Journal of the American Medical Association, 1998, 280(18):1616–1618. World Health Organization. Report: Technical Briefing on Traditional Medicine. Forty-ninth Regional Committee Meeting, Manila, Philippines, 18 September 1998. Manila, WHO Regional Office for the Western Pacific, 1998. World Health Organization. Consultation Meeting on Traditional Medicine and Modern Medicine: Harmonizing the Two Approaches. Geneva, World Health Organization, 1999 (document reference (WP)TRM/ICP/ TRM/001/RB/98–RS/99/GE/ 32(CHN)). World Health Organization. Development of National Policy on Traditional Medicine. A Report of the Workshop on Development of National Policy on Traditional Medicine, 11–15 October 1999, Beijing, China. Manila, WHO Regional Office for the Western Pacific, 1999. World Health Organization. Regional Consultation on Development of Traditional Medicine in South-East Asia Region, 1999. New Delhi, WHO Regional Office for SouthEast Asia, 1999 (document reference SEA/Trad.Med./80). World Health Organization. General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine. Geneva, World Health Organization, 2000 (document reference WHO/EDM/TRM/2000.1). World Health Organization. Promoting the Role of Traditional Medicine in Health Systems: a Strategy for the African Region 2001–2010. Harare, WHO Regional Office for Africa, 2000 (document reference AFR/RC50/ Doc.9/R). Zollman C & Vickers AJ. ABC of Complementary Medicine. London, BMJ Books, 2000 (reprinted from a series of articles that appeared in the British Medical Journal during 1999). See also: http://www.who.int/medicines/ Contacts at WHO Headquarters: Essential Drugs and Medicines Policy Health Technology and Pharmaceuticals Cluster WHO Headquarters, Geneva, Switzerland: Dr Jonathan Quick Director, Essential Drugs and Medicines Policy Department Tel: +41 22 791 4443 Email: quickj@who.int Dr Xiaorui Zhang Acting Team Coordinator, Traditional Medicine Tel: +41 22 791 3639 Email: zhangx@who.int Contacts in WHO Regional Offices: Regional Office for Africa: Dr Ossy Kasilo Traditional Medicines Adviser Tel: +263 4 790 233 E-mail: kasiloo@whoafr.org Regional Office for the Americas: Dr Rosario D’Alessio Regional Adviser for Pharmaceuticals Tel: +1 202 974 3282 E-mail: dalessir@paho.org Dr Sandra Land Regional Adviser, Local Health Services Tel: +1 202 974 3214 E-mail: landsand@paho.org Regional Office for the Eastern Mediterranean: Mr Peter Graaff Regional Adviser, Essential Drugs and Biologicals Tel: +20 2 276 5301 E-mail: graaffp@emro.who.int Regional Office for Europe: Mr Kees de Joncheere Regional Adviser, Pharmaceuticals Tel: +45 3 917 1717 E-mail: cjo@who.dk Regional Office for South-East Asia: Dr Krisantha Weerasuriya Regional Adviser Essential Drugs and Vaccines Tel: +91 11 331 7804 E-mail: weerasuriyak@whosea.org Regional Office for the Western Pacific: Dr Chen Ken Traditional Medicines Adviser Tel: +63 2 528 9948 E-mail: chenk@who.org.ph WHO/EDM/2002.4 Original: English Distr.: General © World Health Organization 2002 This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced and translated, in part or in whole, but not for sale nor for use in conjunction with commercial purposes. The views expressed in documents by named authors are solely the responsibility of those authors
